stockrowPrestige Consumer Healthcare Inc.
PBH Healthcare Drug Manufacturers Specialty & Generic
Prestige Consumer Healthcare Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 billion, down 4.31% from fiscal 2025.
- Revenue
- +22.7%
- EPS
- −38.4%
- Free cash flow
- −38.2%
- Total debt
- +100.9%
Quarter to September 2026, against a year earlier
Follow PBH
Alert me
Prestige Consumer Healthcare Inc. (PBH) Free cash flow
Prestige Consumer Healthcare Inc.'s free cash flow for fiscal 2026 was $246.4M, unchanged from fiscal 2025. Over the twelve months to 30 September 2026 it was $214.2M. Over the past ten years it has ranged from $145.8M (fiscal 2017) to $250.3M (fiscal 2022); the current reading is higher than 92% of that period. Free cash flow has risen for 3 consecutive fiscal years. Prestige Consumer Healthcare Inc. ranks 14th of 84 Drug Manufacturers Specialty & Generic companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2026 | $246.4M | 1.30% |
| FY2025 | $243.3M | 1.64% |
| FY2024 | $239.4M | 7.86% |
| FY2023 | $221.9M | (11.33%) |
| FY2022 | $250.3M | 17.30% |
| FY2021 | $213.4M | 5.33% |
| FY2020 | $202.6M | 13.29% |
| FY2019 | $178.8M | (9.50%) |
| FY2018 | $197.6M | 35.53% |
| FY2017 | $145.8M | (15.78%) |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $34.2M | (48.96%) |
| Jun 2026 | $67.1M | 78.27% |
| Mar 2026 | $37.6M | (50.00%) |
| Dec 2025 | $75.3M | 35.89% |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| BCRX BioCryst Pharmaceuticals, Inc. compare | $366.4M |
| TRLV Trulieve Cannabis Corp. compare | $242.5M |
| PBH Prestige Consumer Healthcare Inc. | $214.2M |
| PRGO Perrigo Company plc compare | $168.2M |
| XERS Xeris Biopharma Holdings, Inc. compare | $73.6M |
| RGC Regencell Bioscience Holdings Limited compare | −$14.7M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −$130.7M |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | −$171.8M |
| ALVO Alvotech compare | −$211.7M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on PBH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement